GlassScriptPhysician profile
Shannon Hall
NPI 1417310921
$2,322.59
in general payments reported to CMS, 2019-2025
21 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $793 · 2024: $1,376 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $542.79 | 2023-2025 | |
| Pfizer INC. | $305.94 | 2023-2024 | |
| Lilly USA, LLC | $226.27 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $167.67 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
| Neurocrine Biosciences, INC. | $128.82 | 2023-2024 | Ingrezza |
| Glaxosmithkline, LLC. | $122.52 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ardelyx, INC. | $111.60 | 2024 | Ibsrela |
| Amgen INC. | $107.87 | 2023-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $104.97 | 2023-2025 | Trintellix |
| Corium, LLC | $92.20 | 2023-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $68.90 | 2023-2025 | Breztri, Farxiga |
| Ironwood Pharmaceuticals, INC | $52.72 | 2023-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.74 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $41.63 | 2024-2025 | Gemtesa |
| Antares Pharma, INC. | $40.45 | 2024-2025 | Xyosted |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.49 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $34.56 | 2024 | Veozah |
| Halozyme INC | $34.18 | 2023 | |
| Shield Therapeutics INC | $19.14 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.41 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $15.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.